Xin Lang Cai Jing·2026-03-23 08:46Core Viewpoint - The announcement indicates that the company's subsidiary has received approval for the production of Ibuprofen granules, which are included in the national medical insurance drug list for 2025, suggesting a significant market opportunity in the pharmaceutical sector [1] Company Summary - The company, through its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Ibuprofen granules from the National Medical Products Administration [1] - The approval of Ibuprofen granules positions the company to capitalize on the growing demand for this medication in the Chinese market [1] Industry Summary - Ibuprofen granules are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List for 2025 [1] - The estimated sales revenue for Ibuprofen-related formulations in Chinese public medical institutions is approximately RMB 4.4 billion in 2024, indicating a substantial market size and potential for growth [1]